Summit Therapeutics SMMT Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's quick ratio?
- Summit Therapeutics (SMMT) reported quick ratio of 7.4× in Q1 2026.
- How has Summit Therapeutics's quick ratio changed year-over-year?
- Summit Therapeutics's quick ratio decreased by 30.3% year-over-year, from 10.6× to 7.4×.
- What is the long-term trend for Summit Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Summit Therapeutics's quick ratio has grown at a 17.5% compound annual growth rate (CAGR), from 4.4× to 9.9×.
- What does quick ratio mean?
- Can the company cover short-term bills without having to sell inventory first?
- How do you interpret quick ratio?
- More conservative than the current ratio. A wide gap between the two flags heavy reliance on inventory to meet near-term obligations.
- How does quick ratio compare across companies?
- Most informative for inventory-heavy businesses; converges with the current ratio for firms that carry little inventory.